Ponatinix, is an oral drug under the generic of Ponatinib, for the first-line therapy of the people affected with chronic myelogenous leukemia.
It is a highly potential and multi-targeted third generation Bcr-Abl tyrosine-kinase inhibitors (TKI) which is indicated for the adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) or Ph+ALL for those who have no other TKI therapy.
It is also indicated for the adult patients with T315I-positive CML (chronic phase, accelerated phase of blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.